Celyad to Participate in Upcoming June 2019 Conferences
29 mai 2019 01h00 HE
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 29, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad to Present Data at 24th Congress of the European Hematology Association
16 mai 2019 16h01 HE
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 16, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights
09 mai 2019 01h00 HE
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 09, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces May 2019 Investor Conference Schedule
02 mai 2019 16h01 HE
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress
17 avr. 2019 16h01 HE
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, April 17, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces April 2019 Investor Conference Schedule
01 avr. 2019 16h01 HE
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, April 01, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Reports Business Update and Full Year 2018 Financial and Operating Results
28 mars 2019 16h05 HE
|
Celyad SA
THINK Phase 1 trial (CYAD-01 with no preconditioning) showed a complete response in 40% of patients with AML/MDSTHINK CyFlu Phase 1 demonstrated CYAD-01 is well-tolerated, with no dose-limiting...
Celyad Appoints Filippo Petti as Chief Executive Officer
28 mars 2019 16h01 HE
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 28, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad to Announce Full Year 2018 Financial Results and Host Conference Call
22 mars 2019 02h00 HE
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 22, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates
18 mars 2019 16h01 HE
|
Celyad SA
shRNA platform complements Company’s all-in-one-vector approach in the design, discovery and development of next-generation CAR-T candidatesAllogeneic T-cells derived by shRNA targeting show...